Our current study identified a major portion of oligodendrogliomas lacking 1p/19q codeletion was characterized by IDH and TERTp co-mutation, with a background of ATRX nuclear positivity wild-type TP53 (Figure 5), indicating that these patients could potentially benefit from chemoradiotherapy. This evidence concerns the gene ATRX and oligodendroglioma.